Season 2 · Episode 396
From Prozac to Plasticity: The New Science of Depression
Herman and Corn explore why we’re moving past SSRIs toward neuroplasticity, ketamine, and the gut-brain axis to treat depression.
My Weird Prompts · Daniel Rosehill
January 31, 202626m 11s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Herman and Corn dive deep into the evolving world of psychopharmacology, moving beyond the outdated "chemical imbalance" theory that has dominated the field for decades. They discuss why traditional SSRIs often fall short and explore the next generation of treatments, including multimodal antidepressants like Trintellix and the rapid-acting potential of NMDA modulators like Auvelity. The conversation also covers the revolutionary shift toward neuroplasticity, the promising but complex landscape of psychedelic-assisted therapy, and the emerging role of the gut-brain axis in mental health. Whether you're curious about personalized medicine through pharmacogenomics or the impact of systemic inflammation on mood, this episode offers a comprehensive look at how we are finally learning to repair the brain rather than just masking its symptoms.